Search clinical trials for: 0.1 mg PF-04995274

Total 968 results

Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Completed

Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

Healthy

United States
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers

Healthy

Belgium
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
University of Oxford

Completed

PF-04995274 and Emotional Processing in Treatment Resistant Depression (RESTART)

Treatment Resistant Depression | Depression, Unipolar

United Kingdom
Pfizer

Terminated

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

Healthy

United States
Pfizer

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (CADENCE)

Hypertension, Pulmonary

United States, Belgium, France, Germany, Israel, Italy, Spain, Sweden, United Kingdom, Poland, Canada
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
H. Lundbeck A/S

Completed

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Parkinson Disease

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (CONGO)

Diabetic Macular Edema (DME)

United States
Shaperon

Completed

Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients

COVID19 Pneumonia

Romania
Kowa Company, Ltd.

Completed

A Clinical Pharmacology Study of K-877 Controlled Release Tablet

Dyslipidemias

Japan
University of Texas Southwestern Medical Center
US Department of Veterans Affairs

Completed

Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer

Rectal Cancer

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Sedation

China
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Laboratorios Sophia S.A de C.V.

Completed

Phase IV Clinical Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PRO-087)

Dry Eye

Mexico
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
Kwang Dong Pharmaceutical co., ltd.

Completed

A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

Overactive Bladder

Korea, Republic of
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Dry Eye Disease

Mexico
Autoimmune Technologies, LLC

Completed

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

Influenza

United States
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Dry Eye Disease

United States
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
Merck Sharp & Dohme LLC

Completed

Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)

Anesthesia
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Pfizer

Completed

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Carcinoma, Breast

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Pfizer

Completed

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Diabetes Mellitus, Type 2

United States, Colombia, Spain, Germany, Sweden, Italy
Atox Bio Ltd

Terminated

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Acute Kidney Injury | Peritonitis | Necrotizing Soft Tissue Infection

United States, France
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Auris Medical AG

Completed

AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

Hearing Loss

Bulgaria
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Cardiox Corporation

Withdrawn

Cardiox Liver Function Test Pivotal Trial (LFT-0002)

Liver Failure | Hepatic Failure

United States
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Shaperon

Recruiting

Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients

COVID-19 Pneumonia

Korea, Republic of
Pfizer

Terminated

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease With Motor Fluctuations

United States

3

Subscribe